Citius Oncology (CTOR) Retained Earnings (2021 - 2026)

Citius Oncology's Retained Earnings history runs 6 years deep, the most recent figure standing at -$96.2 million for Q1 2026.

• In Q1 2026, Retained Earnings fell 79.2% year-over-year to -$96.2 million; the TTM figure through Mar 2026 stood at -$96.2 million (down 79.2% YoY), while the FY2025 annual figure was -$64.0 million, down 63.04% from the prior year.
• Retained Earnings was -$96.2 million for Q1 2026 at Citius Oncology, down from -$69.6 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $345266.0 in Q4 2022 to a low of -$96.2 million in Q1 2026.
• Historically, Retained Earnings has averaged -$30.2 million across 5 years, with a median of -$18.1 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Retained Earnings jumped 3514.08% in 2022, then slumped 179172.62% in 2023.
• A 5-year view of Retained Earnings shows it stood at $345266.0 in 2022, then sank by 675.71% to -$2.0 million in 2023, then plunged by 2211.07% to -$45.9 million in 2024, then slumped by 51.45% to -$69.6 million in 2025, then sank by 38.25% to -$96.2 million in 2026.
• The last three Retained Earnings figures came in at -$96.2 million (Q1 2026), -$69.6 million (Q4 2025), and -$64.0 million (Q3 2025), per Business Quant data.